This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: March 31, 2006
Last updated: December 29, 2014
Last verified: December 2014
The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine) injection has on the way the heart conducts the electrical impulses that allow it to beat effectively. The study will compare Magnevist injection's effect to that of placebo (a saline injection).

Condition Intervention Phase
Healthy Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882) Drug: Moxifloxacin (BAY12-8039) Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Cardiovascular Safety Study of 0.1 and 0.3 mmol/kg Magnevist® Injection at Two Injection Rates (Bolus and 10 mL/15 Sec.) in Normal Subjects Following a Randomized, Cross-over Design Using Placebo and a Concurrent Positive Control

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • The primary study variable was heart-rate corrected QT (QTc) interval [ Time Frame: Within 15 min postinjection ]

Secondary Outcome Measures:
  • Adverse event monitoring, laboratory evaluations [ Time Frame: 24 hrs postinjection ]
  • ECG variables and overall interpretation [ Time Frame: 24 hrs postinjection ]

Enrollment: 71
Study Start Date: January 2004
Study Completion Date: March 2004
Arms Assigned Interventions
Experimental: Arm 1 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
0,1mmol/kg at 10 mL/15 sec
Experimental: Arm 2 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
same dose as arm 1 at bolus rate (2mL/sec)
Experimental: Arm 3 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
0,3mmol/kg at 10 mL/15 sec
Experimental: Arm 4 Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
same dose as arm 3 at bolus rate (2mL/sec)
Active Comparator: Arm 5 Drug: Moxifloxacin (BAY12-8039)
400 mg at 0,07 mL/sec over 60 min
Placebo Comparator: Arm 6 Drug: Placebo
0,9% saline at 0,6mL/kg at bolus rate

Detailed Description:
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, the sponsor of the trial.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with an electrocardiogram [ECG] (normal sinus rhythm [SR], QTc > 450 msec) without clinically significant abnormalities
  • Non-smoker

Exclusion Criteria:

  • History of cardiovascular disease- Pregnant or nursing- Had any contraindication to moxifloxacin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00310596

United States, Florida
Miami, Florida, United States, 33181-3405
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00310596     History of Changes
Other Study ID Numbers: 91024
Study First Received: March 31, 2006
Last Updated: December 29, 2014

Keywords provided by Bayer:
ECG safety

Additional relevant MeSH terms:
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs processed this record on August 23, 2017